Prostate Cancer International is
for 2011 by Great NonProfits
The abstracts of papers to be presented at the annual meeting of the American Urological Association are now available for scrutiny on-line — including by those who are not attending the meeting. Over the next week of so, The “New” Prostate Cancer InfoLink plans to read through these abstracts and comment on the ones that [...]
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: category, Diagnosis, outcome, risk | 8 Comments »
An article just published in Cancer Research this week suggests that adding the investigational agent enzalutamide (MDV3100) to abiraterone acetate and prednisone in men being treated for metastatic, castration-resistant prostate cancer (mCRPC) may be able to further delay disease progression among men showing signs of progression after initial treatment with abiraterone acetate.
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, castration-resistant, enzalutamide, mCRPC, MDV3100 | 2 Comments »
A somewhat surprising paper from Johns Hopkins appears (unsurprisingly) to confirm what the Kattan pre-treatment nomogram has been telling us for years … that higher Gleason scores, higher PSA levels, higher clinical stage, and a higher proportion of biopsy cores being positive for prostate cancer are predictive of higher risk for post-surgical recurrence. metastasis, and [...]
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: outcome, pathology, risk, surgery | 1 Comment »
The April issue of AUA News (a magazine only available to AUA members) includes an interesting article by David Penson, MD, in which he previews a lecture he will be giving at the upcoming annual meeting of the American Urological Association (in Atlanta, later this month).
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: baseline, database, localized, outcone, regitry, standardized, trial | 6 Comments »
There has been a lot of media hype in Europe around the re-presentation of the PIVOT data by Dr. Wilt at the annual meeting of the European Association of Urology in Paris last week. And yet every prostate cancer specialist attending that meeting must have already been well aware of these data.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: Management, obseration, PIVOT, risk, surgery, surveillance, Treatment | 8 Comments »
In the UK, the National Institute for Clinical Excellence (NICE) has just published guidance on the use of focal forms of high-intensity focused ultrasound (HIFU) for the treatment of (low- and intermediate-risk forms of) localized prostate cancer.
Filed under: Diagnosis, Management, Treatment | Tagged: focal, guidance, HIFU, high-intensity focused ultrasound, NICE | 5 Comments »
We finally appear to have mid-term follow-up data from a sizeable series of North American patients with low- and intermediate-risk prostate cancer treated with first-line, high-intensity focused ultrasound (HIFU). The follow-up is limited to a median of 2 years, however, which allows projection of outcomes at 4 years.
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: HIFU, high-intensity focused ultrasound, outcomes | Leave a Comment »
According to a media release from Accuray, Inc., the company has initiated a multi-center, multinational clinical trial in Europe to compare the outcomes of patients with localized prostate cancer treated with CyberKnife stereotactic body radiation therapy (SBRT), da Vinci robot-assisted laparoscopic surgery (RALP), manual laparoscopic surgery (LRP), and conventionally fractionated intensity modulated radiation therapy (IMRT).
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: CyberKnife, IMRT, radiation, SBRT, surgery, trial | 3 Comments »
A new study available on line as a full-text article in European Urology has provided a retrospective analysis of the perioperative outcomes of men undergoing radical prostatectomy for localized prostate cancer in a 15-month period between October 2008 and December 2009 at 20 percent of the community hospitals in the USA (including public hospitals and [...]
Filed under: Diagnosis, Management, Risk, Treatment | Tagged: comparison, open, outcome, radical prostatectomy, RALP, robot-assisted | Leave a Comment »
As many readers of this news service will be aware, good data on the recovery of libido and sexual function after a period of androgen deprivation therapy (ADT) are limited. We have long known that such recovery is variable, and we also know that it can take time, but sound data from a large cohort [...]
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, function, libido, masculinity, potency, serum, sex, testosterone | 4 Comments »
In order to initially gain or maintain board certification, American urologists must (among other things) submit case logs to the American Board of Urology. A new study, published recently in the Journal of Urology, has used data from these case logs to assess current trends regarding the use of robot-assisted laparoscopic and open radical prostatectomy.
Filed under: Management, Treatment | Tagged: open, radical prostatectomy, RALP, robot-assisted, volume | 5 Comments »
Here is a question that is on the minds of many physicians and patients on Planet Prostate Cancer today: Can treatment with abiraterone acetate or similar agents replace the continuous and/or the intermittent first-line use of LHRH-agonist–induced medical castration in patients with high-risk and advanced forms of prostate cancer?
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: abiraterone, enzalutamide, LHRH agonist, MDV3100 | 8 Comments »
In February we reported on a presentation by Sheets et al. at the Genitourinary Cancer Symposium. The presentation addressed the comparative effectiveness and safety of 3D conformal, intensity-modulated, and proton beam forms of radiation therapy (3D-CRT, IMRT, and PBRT, respectively).
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: 3D-CRT, comparative, effectiveness, IMRT, localized, outcome, PBRT, radiation | Leave a Comment »
A report just published on line in The Lancet Oncology provides data from a study of the use of focally directed (as opposed to whole gland) high-intensity focused ultrasound (HIFU) in the treatment of a small series of men with localized prostate cancer between 2007 and 2010. The data are interesting but follow-up to date [...]
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: focal, focused, HIFU, high-intensity, localized, therapy, ultrasound | 12 Comments »
Search for new and
ongoing trials on the
CTAG PCa web site